What is CJC-1295 without DAC, and what is it studied for?

What is the structure of CJC-1295 (no DAC)?

Twenty-nine residues, C-amidated, with the four substitutions above; the D-alanine blocks dipeptidyl-peptidase cleavage and is invisible to mass spectrometry, so the certificate confirms mass and sequence order, not configuration. The DAC version adds a maleimidoproprionic acid linker and a lysine, changing the mass; the comparison post sets the two apart. The product page leaves formula and CAS blank because no registry record has been confirmed.

Identifier	Value
Molecular formula	not recorded
Molecular weight	not recorded
Residues	not recorded
CAS number	not recorded
PubChem CID	not recorded
Current lot	CJC10-0803

How is CJC-1295 (no DAC) thought to work?

Agonist at the GHRH receptor on pituitary somatotrophs, a G-protein-coupled receptor coupled to Gs and cAMP, triggering growth-hormone release in the models that measure it. Jetté and colleagues described the substituted GRF(1-29) backbone and its albumin-conjugated form in 2005.

Which research areas use CJC-1295 (no DAC)?

Area	Typical models and endpoints
GHRH receptor pharmacology	cAMP and growth-hormone release assays in pituitary cell cultures.
Secretagogue combinations	Paired with ipamorelin or GHRP-6 in the same assay to compare receptor routes.
Peptide stability	The four substitutions as a case study in designed protease resistance; comparison with sermorelin.
Analytical chemistry	A 29-mer whose identity rests on LC-MS/MS because no registry record exists for the exact molecule.

What does the published literature show?

Jetté et al. (Endocrinology, 2005) described the substituted GRF(1-29) and its conjugation chemistry in rats; Teichman et al. (Journal of Clinical Endocrinology and Metabolism, 2006) reported the DAC form in healthy adults, a regulated trial that is context only and concerns the albumin-bound molecule. There is no approved product for either form; research use is in-vitro and preclinical.

How is CJC-1295 (no DAC) handled in the laboratory?

Dissolves in water with gentle swirling. Contains methionine at position 27 in native GHRH, replaced by leucine here, so oxidation is less of a concern than for sermorelin; still protect from light. Store lyophilized at minus 20 °C; aliquot and freeze. The concentration table covers volumes and syringe units; the storage guide covers stability by compound class.

What does the current certificate show?

Lot CJC10-0803 tested at 99.76% purity by RP-HPLC (214 nm), identity confirmed by LC-MS/MS, endotoxin <0.05 EU/mL. The certificate is in the COA library and the lot number on the vial matches it. Sold as 10 mg per vial at $110, for laboratory research only.

Certificate history for CJC-1295 (no DAC)

Every certificate the library holds for this compound, newest first. A replaced lot stays listed so the history can be read; the certificate dataset reads all 114 together.

Frequently asked questions

References

1. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.
2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.

Clinical results cited above describe regulated trials of pharmaceutical products and are given as context for research interest only. Nothing on this page describes or recommends use of the material sold here in humans or animals.